+1(646)631-6696
Journal Logo

Journal of Immunology Research and Innovation

OPEN ACCESS

Editorial
Immunogenic cell death and its emerging inducers: the next generation immunotherapy
Yashwant Kumar1 and Alka Bhatia2  
dryashwant@ymail.com

1Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Author Info »



ABSTRACT

Understanding immunogenic cell death (ICD) and its ability to trigger potent antitumor immune responses has revolutionized cancer treatment. Innovative approaches like oncolytic virotherapy, photodynamic therapy (PDT), and nanotechnology have remarkable potential in promoting ICD and enhancing the immune response against cancer. Combining these therapies with immunotherapies improves effectiveness and reduces side effects. ICD can be induced by various agents such as chemotherapeutic drugs, oncolytic viruses, and PDT, activating endoplasmic reticulum stress and generating reactive oxygen species. Nanotechnology plays a crucial role in drug delivery and enhancing ICD induction. These advancements offer a transformative era in cancer treatment, leveraging the immune system's power and promising improved patient outcomes in the fight against cancer.



KEYWORDS

    1. Immunogenic cell death
    2. Immunogenic cell death inducers
    3. Danger-associated molecular patterns
    4. Immunotherapy


Author Info

Yashwant Kumar1 and Alka Bhatia2

1Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India


Corresponding author: dryashwant@ymail.com

© 2025 Reseapro Journals